News

Article

Rheumatoid Arthritis Quiz: Monitoring ILD in RA

Author(s):

Ingrid Torjesen

Interstitial lung disease is a serious life-limiting condition which can occur in people with rheumatoid arthritis. How does one monitor this condition? Test your knowledge with this quiz.

Which the following tests does the American College of Rheumatology recommend to monitor but not to screen for interstitial lung disease in people with systemic autoimmune rheumatic disease such as rheumatoid arthritis?


Related Videos
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Related Content
Hiddo Heerspink, PharmD, PhD | Credit: George Institute for Global Health
October 25th 2024

Semaglutide Shows Promise, Reduces UACR in Nondiabetic Kidney Disease

Patrick Campbell
Square thumbnail for Kidney Compass podcast featuring headshots of hosts and HCPLive logos
October 21st 2024

Kidney Compass: Navigating Clinical Trials

Brendon Neuen, MBBS, PhD Shikha Wadhwani, MD, MS
Will Herrington, MA, MBBS, MD, FRCP, FERA, Professor of Trials and Epidemiology of Kidney Disease, Renal Studies Group, Nuffield Department of Population Health, and practicing Honorary Consultant Nephrologist, Oxford Kidney Unit, Oxford University
October 25th 2024

Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation

Victoria Johnson
Default thumbnail for The Medical Sisterhood with Mona Shahriari, MD
October 18th 2024

The Medical Sisterhood: Motherhood in Medicine, with Alexandra Golant, MD

Mona Shahriari, MD, FAAD
AND017 Receives FDA Orphan Drug Designation for Sickle Cell Disease | Image Credit: US Food and Drug Administration
October 25th 2024

AND017 Receives FDA Orphan Drug Designation for Sickle Cell Disease

Connor Iapoce
Long-Term Tralokinumab Safe, Effective After 6 Years for Atopic Dermatitis
October 25th 2024

Long-Term Tralokinumab Safe, Effective After 6 Years for Atopic Dermatitis

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.